Table 2 presents baseline characteristics of the tau-PET subsample, which was comprised of 32 MCI (13 amnestic, 19 non-amnestic [Supplementary Table 2]) and 28 dementia (20 amnestic-predominant AD-type dementia, 2 frontal variant AD-type dementia, 2 logopenic variant PPA, 3 PCA, 1 unspecified PPA) participants. This evidence concerns the gene MAPT and Alzheimer disease.